Advantages of Aquablation system for patients with BPH

The RAPID-III trial will assess outcomes with flexible cystoscopy with or without the FloStent implant deployed.

The data were presented at the recent American Urological Association Annual Meeting.

Christian Gratzke, MD, explains why an app shows promise for patients with lower urinary tract symptoms.

“Even though there [are] many therapies that one can do, it's not a sign of anything ominous for most men,” says Kevin T. McVary, MD, FACS.

“The differences in patient experience between UroLift System and Rezūm, particularly in terms of early recovery, sexual function, and overall satisfaction, are key considerations for both clinicians and patients selecting a treatment path," says Mark Rochester, MD, FRCS.

The mean change in IPSS from baseline to 3 months was 12.9 in the Aquablation arm vs 13.1 in the LEP arm.